122291-77-4

Upstream product

• 709032-88-2 methyl 2,3,4-tri-O-benzyl-6-deoxy-D-galactopyranoside 
• 129172-95-8 methyl 6-deoxy-α/β-D-galactopyranoside 
• 73-34-7 D-Fucose 

Downstream Products

• 122204-39-1 methyl 2,3,6-tri-O-benzyl-4-O-(2,3,4-tri-O-benzyl-β-D-fucopyranosyl)-β-D-galactopyranoside 
• 122204-38-0 methyl 2,3,6-tri-O-benzyl-4-O-(2,3,4-tri-O-benzyl-α-D-fucopyranosyl)-β-D-galactopyranoside 
• 1092684-34-8 (2S,3S,4R)-2-(hexacosanamido)-1-O-(2,3,4-tri-O-benzyl-α-D-fucopyranosyl)octadecane-1,3,4-triol 
• 122204-37-9 methyl 2,3,6-tri-O-benzoyl-4-O-(2,3,4-tri-O-benzyl-α-D-fucopyranosyl)-β-D-galactopyranoside 

Relevant academic research and scientific papers

RCAI-61, the 6′-O-methylated analog of KRN7000: its synthesis and potent bioactivity for mouse lymphocytes to produce interferon-γ in vivo

RCAI-61, the 6′-O-methylated analog of KRN7000, and six other analogs with modified 6′-position of the galactose moiety of KRN7000 were synthesized to examine their bioactivity for mouse lymphocytes. Methyl α-d-galactopyranoside was the starting material

Immunostimulatory and antitumor activities of monoglycosylceramides having various sugar moieties

Ten kinds of monoglycosylceramides (MonoCers), having the same ceramide portion and different sugar moieties, were synthesized and their immunostimulatory and antitumor activities were examined. The manner of combination between sugar and ceramide has been demonstrated to affect the manifestation of immunostimulatory and resultant antitumor activities of MonoCers, and in the case of D-MonoCers having the D-sugar, α-D-MonoCers (sugar combined to ceramide in an α-configuration) show stronger activities than β-D-MonoCers. Furthermore, the form of sugar, not the furanose-form but the pyranose-form, and the 2- and 4-hydroxyl groups of the pyranose-form of sugar, seemed to play an important role in the manifestation of the activities of α-D-MonoCers.